[Trimethoprim VUFB in the therapy of urinary infections]. / Trimethoprim VUFB pri terapii mocových infekcí.

Twenty women with asymptomatic significant bacteriuria took Trimethoprim (TMP) VUFB, 2 X 200 mg, for eight days. Twelve had morphological changes of the urinary pathways confirmed by intravenous pyelography. The test for the presence of bacteria with an antibody film in the urinary sediment suggested that the infection was in the upper urinary pathways in eight of the women. Immediately after termination of treatment the urine was negative in 16 women (80%), after another three weeks the negative finding persisted in the urine of nine women (45%). In one patient treatment was discontinued after five days on account of dyspeptic complaints, the remaining patients tolerated the drug well.

[Long-term effect of the administration of repeated single doses of netilmicin in urinary tract infections]. / Déletrvajcí úcinek opakovaného jednorázového podání netilmicinu pri infekcích mocových cest.

In 26 patients with different clinical forms of infections of the urinary pathways a 300 mg single dose of netilmicin was administered by the i.m. route and the bacteriological urinary finding was checked for as long as 10 weeks after administration of netilmicin. During this period the urine was bacteriologically negative in 42% of the subjects. In 8 subjects with relapses of the infection a second dose of 300 mg netilmicin was administered and the urine was bacteriologically negative for 10 weeks in four of the patients. On the whole it proved possible to eliminate the urinary infection for 42-112 days in 17 subjects (65%), even in so-called complicated infections. It may be stated that single dose treatment with netilmicin used once or repeatedly leads to prolonged elimination of the infection without affecting the sensitivity of the organisms, without side-effects and with a substantial reduction of the cost of treatment.

[Prevention of recurrent urinary infections using Solco Urovac, a polymicrobial vaccine]. / Profylaxe recidivujících mocových infekcí polymikrobiální vakcínou Solco Urovac.

The administration of Solco Urovac polymicrobial vaccine to 26 patients with recurrent episodes of urinary tract infection significantly reduced the number of episodes, in one third of the persons even prevented them for a period of one year. In case of persistent bacteriuria, accompanying, for example, nephrolithiasis, the vaccine had no effect. A better effect can be achieved in cases of uncomplicated infections of the lower urinary tract than in infections associated with structural abnormalities of the kidneys and urinary tract. In some patients, the administration of the vaccine is accompanied by mild side effects which, but only exceptionally, can lead to the discontinuation of the therapy.

Single-dose treatment with netilmicin for different clinical forms of urinary tract infections.

A group of 44 patients with various clinical forms of urinary tract infections received a single dose of 300 mg netilmicin i.m. The treatment was efficacious in all patients with infections which were negative in the antibody-coated bacteria test and not complicated by anatomic and/or functional abnormalities of the kidneys and urinary tract. After three weeks the recurrence rate was only 19%. Single-dose treatment also proved very effective against urinary tract infections in renal transplant patients whose infection is almost always located in the lower urinary tract. In contrast, the short-term results of treatment were much poorer in complicated infections and particularly in urinary tract infections which were positive in the anti-body-coated bacteria test; here, the recurrence rate was 67%.